DIVAMICS

13 molecular designs. 2 design cycles. ~6 months from project initiation to PCC. ⚡ In developing BGM1812 with BrightGene, DIVAMICS applied its Dynamics-based Drug Discovery (DBDD) framework to optimize a dual AMY3R/CTR agonist for obesity. Instead of synthesizing hundreds of variants, the team built a focused loop: 🎬 Capture the Molecular Movie 🎯 Generate residue-level design hypotheses 🧪 Synthesize high-priority candidates 🔄 Feed experimental data back into simulation Only 13 molecules were designed and fewer than 15 peptides synthesized before the preclinical candidate was identified. The study has been published in the Journal of Medicinal Chemistry. Together with generative capabilities such as DihedralsDiff, DBDD helps teams explore meaningful design space before committing to chemistry. 💬 Where could fewer blind iterations accelerate your current program? #HitToPCC #PeptideEngineering #MolecularDynamics #AIDrugDiscovery #DIVAMICS

From a "Molecular Movie" to clinical proof-of-concept: Scaling mechanism-first drug discovery. 🚀 The story of BGM0504 beautifully illustrates the complete trajectory of DIVAMICS' mechanism-first workflow: 👉 Dynamic Mechanism Rational Molecular Design Experimental Validation Phase III Clinical Proof. For global pharmaceutical and biotech innovators, this framework represents a pragmatic shift from blind, brute-force screening to predictable, explainable engineering. By integrating proprietary physics-based engines (like DihedralsDiff) with rapid wet-lab feedback loops, we deliver: 🔍 Unambiguous Mechanism Hypotheses—knowing why a molecule works. 📉 Fewer Blind Iterations—significantly shrinking synthesis timelines. 🎯 Focused SAR Exploration—maximizing Hit-to-PCC efficiency. This is not a one-off success story. The robust collaboration between DIVAMICS and BrightGene has scaled seamlessly beyond BGM0504. Just recently, our joint efforts yielded BGM1812—an advanced AMY3R/CTR dual agonist for obesity. Its rapid 6-month leap to PCC and its exceptional "fat-loss without muscle-loss" profile were recently featured in the Journal of Medicinal Chemistry (JMC), again powered by our advanced dynamic modeling. The era of relying solely on static structures is evolving. Dynamics-based Drug Discovery (DBDD) is here to make your next program faster, clearer, and translationally secure. 🤝 Are you advancing challenging peptide, TPD, or allosteric programs? Contact us by email: bd@divamics.com #AIDrugDiscovery #BiopharmaBD #HitToPCC #TechBio #PeptideEngineering #Pharmaceuticals #PharmaPartnering #BIO2026 #DIVAMICS

Early drug discovery is a race against information complexity. BioTrajectory AI is now open for its first public beta, helping discovery teams turn scattered research signals into structured insights for early R&D decisions. Registered users will receive 7-day access, including Deep Research Mode. 🎥 Watch the video to see how BioTrajectory AI works — from one research question to an AI-assisted research workflow. Register now: www.biotraj.com #BioTrajectoryAI #AIDrugDiscovery #DrugDiscovery #Biotech #EarlyDiscovery #DIVAMICS

Why DIVAMICS Was Founded: Bringing Computational Power into Real Drug Discovery DIVAMICS was recently featured in "Insight Forum 2026", a video program jointly presented by China Merchants Bank and Suzhou Daily. In the interview, our Founder and CEO, Dr. John Zheng, shared one of the ideas behind DIVAMICS' founding. In many tool-based collaborations, computational platforms can be tested and used — but the real project context often remains limited. Without that context, it is difficult for algorithms to keep improving around the actual questions drug discovery teams face. That realization helped shape DIVAMICS. With a background spanning pharmacy, computational chemistry, and algorithm development, Dr. Zheng set out to bring computational power closer to real innovative drug R&D. He also introduced DIVAMICS' "Molecular Movie" concept: using molecular dynamics to help scientists see how biological molecules and drug molecules interact at the microscopic level. For us, the mission is clear: turn molecular motion into better scientific decisions — and support drug discovery programs that address real industry challenges and clinical needs. #AIDrugDiscovery #MolecularDynamics #DrugDiscovery #ComputationalChemistry #Biotech #DIVAMICS

Turning motion into a precise engineering decision. A deep mechanistic insight only becomes truly valuable when it alters a critical design decision. When engineering BGM0504, we faced a classic peptide tradeoff: How do you extend half-life without compromising dual-receptor activation? In traditional benchmarks like Tirzepatide, acylation is introduced at K20 to support long-acting pharmacokinetics. However, DIVAMICS’ dynamic simulations flagged a major warning: putting a bulky lipid tail directly on K20 disrupts the delicate salt-bridge network required for optimal dual-receptor activation. Guided by this physical insight, our design strategy pivoted completely: 1. Preserve the highly active, native-like K20 salt-bridge interaction. 2. Relocate the long-acting acylated modification away from the core activation machinery. As a result, the acylated side chain in BGM0504 was strategically repositioned to K40 / the C-terminal region. This elegant modification preserved the once-weekly PK profile while unlocking unrestricted, maximal dual-receptor agonism. The Outcome: Preclinical studies, later published in Scientific Reports, confirmed that this mechanism-guided optimization yielded a 2–3x stronger GLP-1R/GIPR agonist activity compared to Tirzepatide. This is the core philosophy of DIVAMICS: We don't just observe molecular motion; we transform physical trajectories into definitive, high-impact drug discovery choices. #PeptideEngineering #RationalDrugDesign #AIDrugDiscovery #Biopharma #MedicinalChemistry #Tirzepatide #BGM0504

What a week at BIO 2026. 🤝 Across booth conversations, partner meetings, media exchanges, and the JLABS closed-door gathering hosted by Johnson & Johnson Innovation, DIVAMICS was grateful to connect with innovators from across the global biotech community. At BIO, we were also excited to introduce BioTrajectory AI, our Data Intelligence Engine for drug discovery, and explore how it can support partners in turning complex discovery data into clearer scientific direction. One thing was clear: Drug discovery is a global collaboration. Thank you to everyone who stopped by, shared ideas, and explored new possibilities with us in San Diego. The conversations started at BIO. The collaborations continue from here. bd@divamics.com #BIO2026 #BIOInternationalConvention #Biotech #DrugDiscovery #PharmaPartnering #BioTrajectoryAI #AIDrugDiscovery #DIVAMICS

From molecular insight to real discovery conversations—DIVAMICS has arrived at BIO 2026 in San Diego Dr. John Zheng, Dr. Hao Liu, and Fanping Meng are now connecting with biotech, pharma, and innovation partners from around the world at BIO 2026. At DIVAMICS, we combine AI, molecular dynamics, and mechanism-first design to help discovery teams look beyond static structures and make more confident Hit-to-PCC decisions. Ahead of the main program, we were also pleased to join an invitation-only JLABS session hosted by Johnson & Johnson Innovation, connecting with fellow APAC innovators. If you are exploring difficult-to-drug targets, molecular design challenges, or early discovery collaborations, we would be glad to meet. 📍 Booth #3943 📩 bd@divamics.com #BIO2026 #JLABS #AIDrugDiscovery #MolecularDynamics #PharmaPartnering

The hidden salt bridge that static structures couldn't catch. Cryo-EM and crystalline snapshots are powerful, but they only tell half the story. Proteins don't sit still in physiological environments — they move, flex, and breathe. In GLP-1/GIP dual agonist engineering, the ultimate challenge is maintaining peak receptor activation while simultaneously extending half-life. Behind BGM0504's exceptional potency lies a dynamic interaction that traditional static structural biology overlooked. By deploying high-performance molecular dynamics (MD) simulations, the DIVAMICS team captured a transient, yet crucial, interaction network revolving around K20 (lysine at position 20 of the peptide). Our "molecular movie" revealed that the flexible K20 side chain forms vital, stabilizing salt-bridge networks: · With E127 & E128 on the GLP-1 Receptor  · With E119 on the GIP Receptor  This dynamic interaction lock essentializes receptor binding and locks the receptor into its fully activated conformation. This is where the Molecular Movie shifts from a visualization tool to programmable drug design logic. By converting transient protein behaviors into quantifiable physical data, we uncover hidden engineering signals that remain invisible to static AI models. Knowing this mechanism was a breakthrough, but how did it fundamentally change our actual engineering decisions? Find out in our next post. #MolecularDynamics #PeptideDesign #ComputationalChemistry #StructuralBiology #Biophysics #GLP1 #ReceptorActivation

What if the next breakthrough in drug discovery starts with watching molecules move? This June, DIVAMICS will be at BIO International Convention 2026 in San Diego — and we'd love to meet teams working on challenging discovery programs. At Booth #3943, we'll be sharing how AI + molecular dynamics can help discovery teams move beyond static structures and make earlier, clearer decisions in: • Difficult-to-drug targets • Peptide and protein-based therapeutics • Mechanism-first molecular design • Hit-to-PCC acceleration • Co-development and technology partnerships If your team is exploring how molecular motion can reveal better design paths, let's connect at BIO 2026. 📍 San Diego Convention Center 📅 June 22-25, 2026 📌 Booth #3943 📩 bd@divamics.com See you in San Diego. #BIO2026 #BIOInternationalConvention #AIDrugDiscovery #MolecularDynamics #DrugDiscovery #Biotech #PharmaPartnering #DIVAMICS

Can physics-based AI redefine the ceiling of weight management? BGM0504 is a BrightGene GLP-1/GIP dual receptor agonist pipeline whose molecular design was supported from the early stage by DIVAMICS' Dynamics-based Drug Discovery (DBDD) approach. The program has now reached a new regulatory milestone: its New Drug Application (NDA) for weight management has been officially accepted for review by China's NMPA/CDE. This follows compelling Phase III study results from a 652-participant clinical study, where the 15mg cohort achieved: • Up to 19.3% mean body weight reduction at Week 52 • 48.9% of participants achieving ≥20% weight loss • 16.5 cm mean waist circumference reduction • Only 0.7% discontinuation due to adverse events For us at DIVAMICS, this is more than a clinical and regulatory milestone. It is a real-world validation of how moving beyond static structures to capturing molecular dynamics can help translate early mechanistic insight into late-stage clinical impact. 🔍 In our next post, we'll look upstream at the “molecular movie” that helped shape the design logic behind BGM0504. #AIDrugDiscovery #ClinicalTrials #GLP1 #WeightManagement #MolecularDynamics #Biotech #DIVAMICS #TechBio